← Human Trials & Peer-Reviewed Studies
The expression and methylation status of vitamin D receptor gene in Behcet's disease.
Plain-language guide to PMID 31709782 (2019): clinical trial of Vitamin D, K2, Magnesium and Zinc in 48 patients.
Key Facts
- PMID
- 31709782
- Journal
- Immunity, inflammation and disease
- Year
- 2019
- Study type
- Clinical Trial
- Authors
- Shirvani SS et al. (8 authors)
- DOI
- 10.1002/iid3.275
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a clinical trial.
The aim of their study was to analyze the expression level and methylation status of the vitamin D receptor (VDR) gene promoter in the peripheral blood mononuclear cells (PBMCs) of patients with BD.
Why It Was Studied
Vitamin D has important roles as a natural immune modulator via regulating the expression of genes which have been implicated in the pathophysiology of autoimmune diseases.
Vitamin D function and its deficiency have been linked to a wide range of metabolic disorders including disorders of calcium metabolism, malignant, cardiovascular, infectious, neuromuscular, and inflammatory diseases.
Who Took Part
According to the abstract, 48 patients were involved.
By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.
In a case-control study, 48 Iranian Azeri patients with BD and 60 age-, sex- and ethnically-matched healthy controls were included.
How the Study Was Run
Venous blood samples were collected and PBMCs were isolated by Ficoll protocol.
The DNA and RNA were subsequently extracted.
Promoter methylation levels were evaluated by MeDIP-quantitative polymerase chain reaction (qPCR).
The expression of VDR was evaluated by real-time PCR.
What Was Measured
The subject headings attached to it are Behcet Syndrome, Case-Control Studies, DNA Methylation, Epigenesis, Genetic and Receptors, Calcitriol.
The authors tagged it with the keywords Behcet's disease, epigenetic, gene expression and vitamin D receptor (VDR).
What This Means in Plain Language
This is a clinical trial of Vitamin D, K2, Magnesium and Zinc in 48 patients.
Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2019 (Immunity, inflammation and disease), a journal based in England.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.